

## GT-MAB 2.5-GEX approved and first clinical trial initiated

Date: 25/11/2009 14:39:22

Italian and German regulatory approval for 'GlycoExpress' Technology and first clinical trial with antibody GT-MAB 2.5-GEX TM

German Biotech company Glycotope, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope's lead antibody GT-MAB 2.5-GEX™ for the treatment of various solid cancers. The approvals further underline the suitability of Glycotope's proprietary 'GlycoExpress' technology for the improvement, glycooptimization and high yield production of therapeutic proteins for the use in humans.

“The approval of GT-MAB 2.5-GEX as well as the regulatory approval of the GlycoExpress production technology based on its glycoengineered human cell lines represents a significant milestone for the company” says Steffen Goletz, PhD, Founder, CEO and CSO of Glycotope. “After generating very encouraging data in pre-clinical studies, we are now looking forward to demonstrate the importance of glycosylation in the clinic by generating a substantial benefit to patients.”

The Phase I study will evaluate the safety and tolerability of GT-MAB 2.5-GEX™ in a broad series of cancer indications.

;

### About GT-MAB 2.5-GEX

GT-MAB 2.5-GEX™ is a novel, exceptionally potent monoclonal antibody for the treatment of a broad variety of cancer indications. The antibody is directed against a novel tumour-specific combined carbohydrate-protein epitope present in a large number of patients of various cancers. GT-MAB 2.5-GEX™ shows three highly effective key modes of anti-tumour action: ADCC, phagocytosis and induction of apoptosis with an exceptionally high and specific tumour accumulation and tumour killing already at doses as low as 0.5 mg/kg.

The antibody's fully human glycosylation is optimized to yield a largely improved ADCC activity, bioavailability and no non-human immunogenic carbohydrate structures. This was achieved by Glycotope's proprietary technology platform GlycoExpress™, a screening and high yield production system of glycoengineered human cell-lines that allows significant enhancement of therapeutic potency by optimizing a protein's glycosylation in various aspects.

;

;

**Source:** [www.b3cnewswire.com](http://www.b3cnewswire.com)

;

